Evidence map›Paper›PMID 36429085›Full record

ArticleCells2022

Low-Dose rIL-15 Protects from Nephrotoxic Serum Nephritis via CD8

Agnes A Mooslechner, Max Schuller, Katharina Artinger, Alexander H Kirsch, Corinna Schabhüttl, Philipp Eller, Alexander R Rosenkranz, Kathrin Eller

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cells, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Agnes A MooslechnerDivision of Nephrology, Department of Internal Medicine, Medical University of Graz, 8036 Graz, Austria.ORCID 0000-0002-3266-3293
Max SchullerDivision of Nephrology, Department of Internal Medicine, Medical University of Graz, 8036 Graz, Austria.
Katharina ArtingerDivision of Nephrology, Department of Internal Medicine, Medical University of Graz, 8036 Graz, Austria.
Alexander H KirschDivision of Nephrology, Department of Internal Medicine, Medical University of Graz, 8036 Graz, Austria.
Corinna SchabhüttlDivision of Nephrology, Department of Internal Medicine, Medical University of Graz, 8036 Graz, Austria.
Philipp EllerIntensive Care Unit, Department of Internal Medicine, Medical University of Graz, 8036 Graz, Austria.ORCID 0000-0001-5537-3646
Alexander R RosenkranzDivision of Nephrology, Department of Internal Medicine, Medical University of Graz, 8036 Graz, Austria.
Kathrin EllerDivision of Nephrology, Department of Internal Medicine, Medical University of Graz, 8036 Graz, Austria.ORCID 0000-0002-6214-5008
Medical University of Graz · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rapid progressive glomerulonephritis (GN) often leads to end-stage kidney disease, driving the need for renal replacement therapy and posing a global health burden. Low-dose cytokine-based immunotherapies provide a new strategy to treat GN. IL-15 is a strong candidate for the therapy of immune-mediated kidney disease since it has proven to be tubular-protective before. Therefore, we set out to test the potential of low-dose rIL-15 treatment in a mouse model of nephrotoxic serum nephritis (NTS), mimicking immune complex-driven GN in humans. A single low-dose treatment with rIL-15 ameliorated NTS, reflected by reduced albuminuria, less tissue scarring, fewer myeloid cells in the kidney, and improved tubular epithelial cell survival. In addition, CD8

Indexed as

GlomerulonephritisNephritisAnimalsCD8-Positive T-LymphocytesHumansInterleukin-15KidneyMiceMice, KnockoutInterleukin-15glomerulonephritisinterleukin-15renal tubular epithelial cell

Identifiers

PMID36429085
PMCPMC9688325
OpenAlexW4309455798

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.